Elon Musk ignited a social media storm on X, questioning the handling of the Epstein case and taking veiled swipes at Donald ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined efficacy thresholds” in a phase 2 study. | Novartis has ended work on ...

Elon Musk has publicly questioned Donald Trump regarding the unreleased Epstein files. Musk's tweet criticized Trump's promise of transparency. Trump's earlier defense of Pam Bondi and accusations ...

OKYO Pharma (NASDAQ:OKYO) stock jumped 14% Wednesday after announcing encouraging Phase 2 clinical trial results for urcosimod, their investigational drug aimed at neuropathic corneal pain (NCP). The ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

After the Grenfell fire there are many lessons to be learned. Architects and manufacturers should be able to demonstrate they ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

Amirco Properties, a real estate company, is expected to break ground on the 4-acre, multi-building development—dubbed ...

It’ll be the 5th and 6th ones they’ve built so far. This partnership has been in the making since 2022, and Bright Community Trust broke ground on their first houses here in Gainesville in 2024. The ...